VYNE THERAPEUTICS INC (VYNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.50+8.46%
Close 2026-08-24 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VYNE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenues | 0.6 | 0.5 | 0.4 | 0.5 | 0.9 | 21.0 |
| Cost of Revenues | — | — | — | — | 3.3 | 1.4 |
| Operating Expenses & Income | ||||||
| Selling, General & Admin | — | — | — | 16.4 | 20.3 | 89.5 |
| R&D Expenses | 19.2 | 30.9 | 16.3 | 18.4 | 19.5 | 43.5 |
| Operating Income | (29.7) | (43.6) | (29.3) | (34.3) | (38.9) | (252.5) |
| Earnings from Continuing Operations | ||||||
| Interest Expense | — | — | — | 0.0 | 5.6 | 4.4 |
| EBT, Incl. Unusual Items | (26.7) | (39.8) | (27.9) | (33.9) | (44.7) | (255.8) |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | (0.4) | (0.3) |
| Net Income | ||||||
| Net Income | (26.5) | (39.8) | (28.5) | (23.2) | (73.3) | (255.6) |
| Per Share | ||||||
| Basic EPS | (0.62) | (0.93) | (2.78) | (7.28) | (25.64) | 7.88 |
| Diluted EPS | (0.62) | (0.93) | (2.78) | (7.28) | (25.64) | 7.88 |
| Basic Weighted Avg Shares | 42.8 | 42.6 | 10.3 | 3.2 | 2.9 | 32.4 |
| Diluted Weighted Avg Shares | 42.8 | 42.6 | 10.3 | 3.2 | 2.9 | 32.4 |
| Supplemental | ||||||
| EBITDA | (29.7) | (43.6) | (29.3) | (34.2) | (38.8) | (252.2) |
| EBIT | (29.7) | (43.6) | (29.3) | (34.3) | (38.9) | (252.5) |
| Effective Tax Rate | — | — | 0.0% | -0.0% | 1.0% | 0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.